ADC Therapeutics’ Zynlonta-glofitamab combination shows 88.7% response rate in Phase 1b lymphoma trial

Bitget2026/11/04 14:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ADC Therapeutics will present Zynlonta clinical results at the American Society of Hematology meeting, December 12-15, 2026, in New Orleans.
Phase 3 LOTIS-5 showed Zynlonta with rituximab delayed disease progression versus R-GemOx in relapsed or refractory DLBCL, without significantly improving overall survival.
Fatal adverse events were more frequent with Zynlonta under the protocol-defined reporting window, but less frequent under a shorter post-treatment window.
Updated Phase 1b LOTIS-7 results showed durable responses with Zynlonta combined with glofitamab, supporting further Phase 3 investigation.
A Phase 2 marginal zone lymphoma study showed durable complete responses with Zynlonta monotherapy, supporting potential expansion into additional treatment settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611040900PR_NEWS_USPR_____NY88478) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ADC Therapeutics’ Zynlonta-glofitamab combination shows 88.7% response rate in Phase 1b lymphoma trial

You may also like

Crypto prices